Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient

被引:13
作者
Fragulidis, Georgios [1 ]
Pantiora, Eirini [1 ]
Michalaki, Vasiliki [2 ]
Kontis, Elissaios [1 ]
Primetis, Elias [3 ]
Vezakis, Antonios [1 ]
Polydorou, Andreas [1 ]
机构
[1] Univ Athens, Aretaieio Hosp, Sch Med, Dept Surg 2, 76 Vas Sophias Ave, Athens 11528, Greece
[2] Univ Athens, Aretaieio Hosp, Sch Med, Dept Oncol, Athens, Greece
[3] Univ Athens, Aretaieio Hosp, Sch Med, Dept Radiol 1, Athens, Greece
关键词
Immune-related pseudo-obstruction; nivolumab; lung adenocarcinoma; immune checkpoint inhibitor; adverse effects; CHECKPOINT INHIBITORS; DOCETAXEL;
D O I
10.1177/1078155217738325
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immune checkpoint inhibition therapy using targeted monoclonal antibodies is a new therapeutic approach with significant survival benefit for patients with several cancer types. However, their use can be associated with unique immune-related adverse effects as a consequence of impaired self-tolerance due to loss of T-cell inhibition via a nonselective activation of the immune system. Nivolumab is an anti-PD-1 immune checkpoint inhibitor that was recently developed for cancer immunotherapy with remarkable responses in nonsmall cell lung cancer patients. We present a 62-year-old Caucasian male with recurrent lung adenocarcinoma and currently under third-line therapy with nivolumab, who was admitted in our hospital with abdominal distension. Radiologic findings were consistent with small bowel ileus. After four days of conservative treatment, the patient underwent exploratory laparotomy where no cause of ileus was discovered. Postoperative the ileus persisted and considering that an adverse effect of the immune checkpoint inhibition therapy occurred, the patient received high-dose prednisone resulting in gradual improvement of symptoms. Immune checkpoint inhibitors may induce adverse effects to unaffected organ systems and tissues including the skin, gastrointestinal, hepatic, pulmonary, and endocrine system. The mainstay treatment consists of immunosuppression with corticosteroids in the majority of cases. As the clinical use of immune checkpoint inhibitors is expanding rapidly, there is an emergence of unique immune-related adverse effects in a growing patient population. Gaining early awareness is essential in these patients in order to ensure prompt diagnosis and management.
引用
收藏
页码:487 / 491
页数:5
相关论文
共 50 条
[21]   Nivolumab-induced immune-related neutropenia in a renal cell carcinoma patient [J].
Kalaci, Ender ;
Urun, Yuksel .
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (07) :1797-1801
[22]   Immune-related Neurological Symptoms in an Adolescent Patient Receiving the Checkpoint Inhibitor Nivolumab [J].
Tchapyjnikov, Dmitry ;
Borst, Alexandra J. .
JOURNAL OF IMMUNOTHERAPY, 2017, 40 (07) :286-288
[23]   Immune-related adverse events caused by treatment with pembrolizumab in a patient with lung cancer who infected influenza virus [J].
Takemura, Masao ;
Motegi, Mitsuru ;
Kuroiwa, Yuya ;
Itai, Miki ;
Taguchi, Kohei ;
Umetsu, Kazue ;
Uchida, Megumi ;
Kounoc, Shunichi ;
Sato, Mari ;
Masubuchi, Hiroaki ;
Yamaguchi, Aya ;
Yamaguchi, Koichi ;
Ikeda, Kana ;
Nakagawa, Junichi ;
Maeno, Toshitaka .
RESPIRATORY MEDICINE CASE REPORTS, 2021, 32
[24]   Treatment options for immune-related adverse events associated with immune checkpoint inhibitors [J].
Chen, Yu Hua ;
Kovacs, Tamas ;
Ferdinandy, Peter ;
Varga, Zoltan V. .
BRITISH JOURNAL OF PHARMACOLOGY, 2024,
[25]   Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer [J].
Shao, Jun ;
Wang, Chengdi ;
Ren, Pengwei ;
Jiang, Yuting ;
Tian, Panwen ;
Li, Weimin .
BIOSCIENCE REPORTS, 2020, 40
[26]   Granuloma-forming interstitial pneumonia induced by nivolumab: a possible immune-related adverse event of the lung [J].
Takeru Kashiwada ;
Yoshinobu Saito ;
Yuji Minegishi ;
Nariaki Kokuho ;
Akihiko Takahashi ;
Satoshi Takahashi ;
Kenichiro Atsumi ;
Masahiro Seike ;
Arata Azuma ;
Kaoru Kubota ;
Yasuhiro Terasaki ;
Akihiko Gemma .
International Cancer Conference Journal, 2017, 6 (3) :131-134
[27]   Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer [J].
Atsuto Mouri ;
Kyoichi Kaira ;
Ou Yamaguchi ;
Ayako Shiono ;
Yu Miura ;
Kosuke Hashimoto ;
Fuyumi Nishihara ;
Yoshitake Murayama ;
Kunihiko Kobayashi ;
Hiroshi Kagamu .
Cancer Chemotherapy and Pharmacology, 2019, 84 :873-880
[28]   Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer [J].
Mouri, Atsuto ;
Kaira, Kyoichi ;
Yamaguchi, Ou ;
Shiono, Ayako ;
Miura, Yu ;
Hashimoto, Kosuke ;
Nishihara, Fuyumi ;
Murayama, Yoshitake ;
Kobayashi, Kunihiko ;
Kagamu, Hiroshi .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (04) :873-880
[29]   Rheumatoid Arthritis Symptoms Diagnosed by Rheumatic Immune-related Adverse Events Caused by Nivolumab in a Patient with Esophageal Cancer [J].
Yasui, Sho ;
Yoshida, Akira ;
Takata, Miki ;
Kamitani, Yu ;
Nakada, Yusuke ;
Kurumi, Hiroki ;
Ikebuchi, Yuichiro ;
Kawaguchi, Koichiro ;
Yashima, Kazuo ;
Isomoto, Hajime .
INTERNAL MEDICINE, 2023, 62 (02) :215-220
[30]   Risk factors for severe immune-related pneumonitis after nivolumab plus ipilimumab therapy for non-small cell lung cancer [J].
Sumi, Toshiyuki ;
Sekikawa, Motoki ;
Koshino, Yuta ;
Nagayama, Daiki ;
Nagahisa, Yuta ;
Matsuura, Keigo ;
Shijubou, Naoki ;
Kamada, Koki ;
Suzuki, Keito ;
Ikeda, Takumi ;
Michimata, Haruhiko ;
Watanabe, Hiroki ;
Yamada, Yuichi ;
Osuda, Koichi ;
Tanaka, Yusuke ;
Chiba, Hirofumi .
THORACIC CANCER, 2024, 15 (20) :1572-1581